Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05050084
Title Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score
Recruitment Recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors NRG Oncology
Indications

prostate adenocarcinoma

Therapies

Buserelin

Relugolix

Degarelix

Goserelin

Leuprolide

Histrelin acetate

Triptorelin

Darolutamide + Goserelin

Bicalutamide

Darolutamide + Degarelix

Darolutamide + Leuprolide

Darolutamide + Triptorelin

Buserelin + Darolutamide

Darolutamide + Histrelin acetate

Flutamide

Darolutamide + Relugolix

Age Groups: senior | adult
Covered Countries USA | CAN


No variant requirements are available.